SUMMARY OF THE 2015 ANNUAL REPORTING OF SERIOUS ADVERSE EVENTS AND REACTIONS (SARE) FOR BLOOD AND BL
Blood transfusion is a critical pillar supporting many different healthcare specialities across the European Union, with millions of patients receiving donated blood and blood components every year. However, the use of any substance of human origin carries some risk, notably the possible transmission of infectious diseases from the donor. These risks can be controlled and minimised by the application of comprehensive safety and quality measures; such measures are laid down in EU legislation. Despite these measures, rare adverse outcomes are detected and, in line with the legislation, these must be reported and monitored at a national and EU level through vigilance and surveillance programmes.
Click on this link for more information.
